Century Therapeutics, Inc. (IPSC) Stock Research
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Latest price: 1.51 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Carr Douglas | sell | 2026-11-03 | 404.05 |
| Russotti Gregory | sell | 2026-09-14 | 4992.91 |
| Carr Douglas | sell | 2026-09-14 | 3199.94 |
| Carr Douglas | sell | 2026-09-08 | 520.7 |
| Russotti Gregory | sell | 2026-09-08 | 1094.7 |
| Carr Douglas | sell | 2026-08-03 | 543.68 |
| Carr Douglas | sell | 2026-06-12 | 3691.73 |
| Russotti Gregory | sell | 2026-06-12 | 5767.49 |
| Carr Douglas | sell | 2026-05-04 | 618.02 |
| Carr Douglas | sell | 2026-03-12 | 17952.61 |